Industry

ROUEN, France–(BUSINESS WIRE)–This strategic alliance formed by UbiPharm and Imperial, both significant logistics and distribution players in the healthcare industry in Africa, will provide complementary continental route-to-market solutions to healthcare principals and clients, leveraging best-in-class operations and commercial services. While UbiPharm and Imperial will each maintain their individual business autonomies, the strategic alliance will drive … [Read more…]

GHENT, Belgium–(BUSINESS WIRE)–Confo Therapeutics announced today that it has been awarded a EUR 1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The award further validates and supports Confo’s leadership in the discovery of novel GPCR (G protein-coupled receptor) drug candidates using its proprietary universal ConfoBody® technology, specifically for the purpose of developing needed new … [Read more…]

The team led by Prof. Karaaltin, employed revolutionary techniques to save lives of conjoined twins ISTANBUL–(BUSINESS WIRE)–A Turkish medical team has successfully separated conjoined twins shortly after birth by employing a range of innovative techniques, including virtual simulations and 3D modeling. Carried out at Istanbul’s Acibadem Hospital, the successful procedure set a new world record … [Read more…]

PARIS–(BUSINESS WIRE)–Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a collaboration with Galapagos, a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of Galapagos drug discovery programs. Under the agreement, Iktos will apply … [Read more…]

STRASBOURG, France & LUND, Sweden–(BUSINESS WIRE)–#HBV–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announced a clinical trial collaboration and … [Read more…]

Center slated to open in late 2023; will serve as a state-of-the-art hub for managing and coordinating complex medical supply logistics for WVU Medicine Groundbreaking advances the long-term strategic collaboration between WVU Medicine and Owens & Minor to help strengthen healthcare resiliency and preparation in West Virginia and beyond RICHMOND, Va.–(BUSINESS WIRE)–Owens & Minor, Inc. … [Read more…]

TORONTO–(BUSINESS WIRE)–Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today an update on the status of its previously-announced proposed acquisition (the “Acquisition”) of Check Five LLC, a Delaware limited liability company (doing business as “Success TMS”) (“Success TMS”). … [Read more…]

– NDA Resubmission Addresses Issues Related to Vial Compatibility – – If Approved, Lenacapavir Would be the First and the Only HIV-1 Treatment Option Administered Twice-Yearly – FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, … [Read more…]

DUBLIN, Calif.–(BUSINESS WIRE)–Vagaro and Thrivo recently announced they will co-host a free Pride celebration at the first-ever Metaverse salon on June 30th to officially close out Pride Month. The virtual dance party will take place on the rooftop of the Thrivo Salon, located in the Fashion District of Decentraland, at 4pm PT/7pm ET. Virtual partygoers … [Read more…]

11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months 6 of 17 patients (35.2%) achieved a complete renal response, including a UPCR of 0.5 or less at 6 months Zetomipzomib continues to demonstrate a favorable safety and tolerability profile … [Read more…]